Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

CAR T-cell Therapy for Multiple Myeloma at Sheba

T-cell Therapy for Multiple Myeloma is available at Sheba Medical Center in Israel
Previously offered only to patients with leukemia and lymphoma, CAR T-cell therapy is now available as a treatment for multiple myeloma at Sheba.

CAR T-cell therapy is a revolutionary blood cancer treatment that helps the body combat tumors using its own T-cells. The therapy involves collecting the patient’s blood, separating T-cells, and genetically engineering them to produce chimeric antigen receptors (CARs). These allow the T-cells to recognize tumor cells, targeting and destroying them. After their alteration, T-cells are multiplied in a laboratory and then reintroduced to the patient’s body.

CAR T-cell therapy is a cutting-edge treatment available only at a limited number of cancer centers worldwide. At Sheba, CAR T-cell therapy has been offered since 2015, with over 220 patients who have undergone the therapy since. 

Until recently, Sheba offered CAR T-cell therapy for acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma. Following recent FDA approval, we are pleased to announce that CAR T-cell therapy is now available for the treatment of multiple myeloma patients.

By choosing Sheba for treatment, multiple myeloma patients can benefit from the experience of world-renowned specialists, including Prof. Arnon Nagler, President of the Hemato-Oncology Division, as well as end-to-end treatment in one facility.

Commenting on the addition of CAR T-cell therapy to the multiple myeloma therapeutic arsenal, Director of the Multiple Myeloma Unit at Sheba, Dr. Hila Magen, explained: “We are talking about an advanced immunotherapy that ‘re-educates’ the patient’s immune system to fight cancerous myeloma cells. It is truly an incredible breakthrough that opens the door for new multiple myeloma therapeutic approaches.” 

Sheba Leverages ChatGPT
Accelerating Diagnostics: ChatGPT Results Aligned with Breast Cancer Board Recommendations
Recently, several distinguished Sheba clinicians were impressed by the tool’s capabilities. The group, which included Dr. Vera Sorin, Dr. Eyal Klang, Dr. Miri Sklair-Levy, Prof.…
Read More
Sheba and Vidac
Novel Drug Set to Improve CAR T-Cell Therapy Effectiveness
While many medical centers around the world depend on external labs to genetically engineer patient T-cells, a process that can take up to a few…
Read More
Sheba Named Global Oncology Leader
by Newsweek Magazine
Dedicated to providing those in need across the globe ‘Hope Without Boundaries,’ Sheba treats patients from more than 100 countries each year, employing the latest…
Read More